Sign up Australia
Proactive Investors - Run By Investors For Investors
Why invest in RGS?
Regeneus: THE INVESTMENT CASE

Regeneus: Access latest PPT from Proactive's CEO Sessions

John Martin discussed regenerative medicine with investors.
Regeneus: Access latest PPT from Proactive's CEO Sessions
INVESTMENT OVERVIEW: RGS The Big Picture
John Martin, chief executive officer, Regeneus

Regeneus (ASX:RGS) chief executive officer, John Martin, joined Proactive's CEO Sessions in Sydney on Wednesday 14th June and Melbourne on Thursday 15th June.

The company provides exposure to the rapid growth global regenerative medicine market, utlising its world-calss stem cell and immuno-oncology technology platforms.

Its technology has been validated by positive pre-clinical and clinical data, and by a collaboration with a leading biopharma manufacturer in Japan.
 

ACCESS THE FULL PRESENTATION HERE



Register here to be notified of future RGS Company articles
View full RGS profile View Profile

Regeneus Timeline

Related Articles

hepatitisC.jpg
March 28 2017
Regulatory sign-off will fire the starting pistol on the commercial launch in Europe
antibiotic.jpg
April 18 2017
Iclaprim is one of the next-generation of antibiotics and it will be used, initially at least, to treat acute bacterial skin and skin structure infections
shutterstock_216375733.jpg
January 25 2017
At the moment, the healthcare firm M Pharma is a work in progress

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use